健康な参加者を対象としたLY4515100の研究
LY4515100の安全性、忍容性、および薬物動態を特徴づけるための第1相、無作為化、研究者および被験者二重盲検、プラセボ対照、単回および反復漸増投与試験:健康な被験者を対象として
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 電話番号:1-317-615-4559
- メール:LillyTrials@Lilly.com
研究連絡先のバックアップ
- 名前:Physicians interested in becoming principal investigators please contact
- メール:clinical_inquiry_hub@lilly.com
研究場所
-
-
Texas
-
Dallas、Texas、アメリカ、75247
- 募集
- Fortrea Clinical Research Unit
-
主任研究者:
- Gene Voskuhl
-
コンタクト:
- 電話番号:866-429-3700
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53704
- 募集
- Fortrea Clinical Research Unit
-
主任研究者:
- Kimberly Cruz
-
コンタクト:
- 電話番号:866-429-3700
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.
-
Have a body mass index (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).
-
Individuals not of childbearing potential (INOCBP) may participate in this trial.
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- must be 18 to 45 years of age (inclusive).
- have a BMI within the range of 18.5 to 30 kg/m².
- may be healthy pre-menopausal assigned female at birth (AFAB) individuals of child bearing potential (IOCBP).
Exclusion Criteria:
-
Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.
-
Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.
-
Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator.
-
Participants with an estimated glomerular filtration rate less than (<) 90 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
-
Have a 12-lead Electrocardiogram (ECG) abnormality that, in the opinion of the investigator,
-
increases the risks associated with participating in the study
-
may confound ECG data analysis
-
Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing.
-
Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions.
-
Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable)
-
Show evidence of
-
Human immunodeficiency virus (HIV) infection and/or positive human HIV antigen and/or antibodies
-
hepatitis C and/or positive hepatitis C antibody
-
hepatitis B and/or positive hepatitis B surface antigen.
-
Have liver disease.
-
Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment.
-
Part C Only:
- Have history of neuropathy of any cause.
- Have impaired hearing or a history of hearing problems.
- Have any medical conditions, medical history, or are taking any medications that are contraindicated in the itraconazole prescribing information, such as prior history of hypersensitivity to itraconazole or other azoles.
- Participants with any known history of thyroid disease
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- Are current smokers or have used nicotine, including tobacco or nicotine replacement products within 14 days prior to the first dose of combined oral contraceptive (COC), or plan to use nicotine, including tobacco or nicotine replacement products during the study.
- Are at high risk for arterial or venous thrombotic diseases, autoimmune disease with lupus anticoagulants or anti-phospholipid syndrome, major surgery within the past 3 months, anticipated prolonged immobility.
- Have abnormalities indicative of increased risk of VTE on the thrombophilia panel at screening.
- Have undiagnosed abnormal uterine bleeding.
- Have any history of breast, uterine or ovarian cancer.
- Use of Vitamin C (greater than or equal to (≥) 500 mg/day) or acetaminophen within 14 days before dosing.
- Have contraindications for the use of levonorgestrel/ethinyl estradiol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:LY4515100 of Part A (SAD)
Single-ascending doses of LY4515100 will be given orally |
given orally |
|
実験的:LY4515100 of Part B (MAD)
Multiple-ascending doses of LY4515100 will be given orally |
given orally |
|
実験的:LY4515100 and Itraconazole of Part C
LY4515100 and Itraconazole will be given orally |
given orally given orally |
|
実験的:LY4515100 and Metformin of Part C
LY4515100 and Metformin will be given orally |
given orally given orally |
|
実験的:LY4515100 and Transporter Substrates or Renal Marker of Part C
LY4515100 and Transporter Substrates or Renal Marker will be given either orally or intravenously (IV) |
given orally given orally given orally given IV given orally |
|
実験的:LY4515100 and Midazolam of Part C
LY4515100 will be given orally. Midazolam will be given orally and IV. |
given orally given orally given IV |
|
実験的:LY4515100 and Combined Oral Contraceptive of Part C
LY4515100, Levonorgestrel, and Ethinyl Estradiol will be given orally |
given orally given orally given orally |
|
プラセボコンパレーター:Placebo Part A
Placebo will be given orally |
given orally |
|
プラセボコンパレーター:Placebo Part B
Placebo will be given orally |
given orally |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B
時間枠:Day 1 up to Day 30
|
SAEs of LY4515100 |
Day 1 up to Day 30
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PK: Geometric Means of Area Under the Concentration-Time Curve From 0 to Infinity [AUC(0-∞)] of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
時間枠:Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of Cmax of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
時間枠:Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of AUC(0-∞) of Substrate in Combination with LY4515100 versus Substrate Alone
時間枠:Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
PK: Geometric Means of Cmax of Substrate in Combination with LY4515100 versus Substrate Alone
時間枠:Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY4515100
時間枠:Day 1 through Day 11
|
PK: AUC of LY4515100 |
Day 1 through Day 11
|
|
PK: Maximum Observed Drug Concentration (Cmax) of LY4515100
時間枠:Day 1 through Day 11
|
PK: Cmax of LY4515100 |
Day 1 through Day 11
|
|
PK: Time of maximum observed drug concentration (tmax) of LY4515100
時間枠:Day 1 through Day 11
|
PK: tmax of LY4515100 |
Day 1 through Day 11
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- ホルモン
- ホルモン、ホルモン代替品、ホルモン拮抗薬
- 硫黄化合物
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- アゾール
- 炭化水素
- 炭化水素、周期的
- 炭水化物
- カルボン酸
- アルカロイド
- 炭化水素、芳香
- 多環式化合物
- グリコシド
- アミド
- ピリノン
- プリン
- ピリミジン
- ステロイド
- 融合リング化合物
- ベンゼン誘導体
- 炭化水素、ハロゲン化
- ベンザゼピン
- エストラジオール同族体
- ゴナダルステロイドホルモン
- ゴナダルホルモン
- Biguanides
- グアニジン
- アミジン
- 酸、炭素環
- スルホンアミド
- スルホン
- ベンゾエート
- ベンゾジアゼピン
- トリアゾール
- フルオロベンゼン
- 炭化水素、フッ素化
- ピペラジン
- ノルペレグネネス
- ノルプレグナン
- 核
- キサンチン
- トリオヨードベンゾ酸
- ヨードベンゾエート
- ジジタリスグリコシド
- カルデノリド
- 心臓のグリコシド
- カルダノリド
- Norpregnatrienes
- エストロゲン性ステロイド、アルキル化
- ノルスレル
- ロスバスタチンカルシウム
- ミダゾラム
- ジゴキシン
- メトホルミン
- カフェイン
- イトラコナゾール
- レボノルゲストレル
- エチニルエストラジオール
- Iohexol
その他の研究ID番号
- 27789
- J6V-MC-OIAB (その他の識別子:Eli Lilly and Company)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。